Adverse effects to risperidone therapy may include headache, nausea, dizziness, tachycardia, orthostatic hypotension and dyskinesia.
See Compliance Statement B
Statement B: This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.